This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Patterson, A. V. Articles by Wilson, W. R. Search for Related Content PubMed PubMed Citation Articles by Patterson, A. V. Articles by Wilson, W. R.

Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104

Authors' Affiliation: Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, New Zealand

Requests for reprints: William R. Wilson, Auckland Cancer Society Research Centre, The University of Auckland, Private Bag 92019, Auckland, New Zealand. Phone: 64-9-3737599, ext. 86886; Fax: 64-9-3737571; E-mail: wr.wilson{at}auckland.ac.nz.

Purpose: Hypoxia is a characteristic of solid tumors and a potentially important therapeutic target. Here, we characterize the mechanism of action and preclinical antitumor activity of a novel hypoxia-activated prodrug, the 3,5-dinitrobenzamide nitrogen mustard PR-104, which has recently entered clinical trials.

Experimental Design: Cytotoxicity in vitro was evaluated using 10 human tumor cell lines. SiHa cells were used to characterize metabolism under hypoxia, by liquid chromatography-mass spectrometry, and DNA damage by comet assay and H2AX formation. Antitumor activity was evaluated in multiple xenograft models (PR-104 ± radiation or chemotherapy) by clonogenic assay 18 h after treatment or by tumor growth delay.

Results: The phosphate ester "pre-prodrug" PR-104 was well tolerated in mice and converted rapidly to the corresponding prodrug PR-104A. The cytotoxicity of PR-104A was increased 10- to 100-fold by hypoxia in vitro. Reduction to the major intracellular metabolite, hydroxylamine PR-104H, resulted in DNA cross-linking selectively under hypoxia. Reaction of PR-104H with chloride ion gave lipophilic cytotoxic metabolites potentially able to provide bystander effects. In tumor excision assays, PR-104 provided greater killing of hypoxic (radioresistant) and aerobic cells in xenografts (HT29, SiHa, and H460) than tirapazamine or conventional mustards at equivalent host toxicity. PR-104 showed single-agent activity in six of eight xenograft models and greater than additive antitumor activity in combination with drugs likely to spare hypoxic cells (gemcitabine with Panc-01 pancreatic tumors and docetaxel with 22RV1 prostate tumors).

Conclusions: PR-104 is a novel hypoxia-activated DNA cross-linking agent with marked activity against human tumor xenografts, both as monotherapy and combined with radiotherapy and chemotherapy.

This article has been cited by other articles:

				Q.-T. X. Le, J. Moon, M. Redman, S. K. Williamson, P. N. Lara Jr, Z. Goldberg, L. E. Gaspar, J. J. Crowley, D. F. Moore Jr, and D. R. Gandara Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: SWOG 0222 J. Clin. Oncol., June 20, 2009; 27(18): 3014 - 3019. [Abstract] [Full Text] [PDF]

				Y. Gu, A. V. Patterson, G. J. Atwell, S. B. Chernikova, J. M. Brown, L. H. Thompson, and W. R. Wilson Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A Mol. Cancer Ther., June 1, 2009; 8(6): 1714 - 1723. [Abstract] [Full Text] [PDF]

				R. S. Singleton, C. P. Guise, D. M. Ferry, S. M. Pullen, M. J. Dorie, J. M. Brown, A. V. Patterson, and W. R. Wilson DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity Cancer Res., May 1, 2009; 69(9): 3884 - 3891. [Abstract] [Full Text] [PDF]

				S.-C. Liu, G-O. Ahn, M. Kioi, M.-J. Dorie, A. V. Patterson, and J. M. Brown Optimized Clostridium-Directed Enzyme Prodrug Therapy Improves the Antitumor Activity of the Novel DNA Cross-Linking Agent PR-104 Cancer Res., October 1, 2008; 68(19): 7995 - 8003. [Abstract] [Full Text] [PDF]

				K. A. Krohn, J. M. Link, and R. P. Mason Molecular Imaging of Hypoxia J. Nucl. Med., June 1, 2008; 49(Suppl_2): 129S - 148S. [Abstract] [Full Text] [PDF]

				W. R Wilson, K. O Hicks, F. B Pruijn, and A. V Patterson Targeting Tumor Hypoxia with Prodrugs: Challenges and Opportunities Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 293 - 310. [Abstract] [Full Text] [PDF]

				N. A. Helsby, M. A. Goldthorpe, M. H. Y. Tang, G. J. Atwell, E. M. Smith, W. R. Wilson, and M. D. Tingle Influence of Mustard Group Structure on Pathways of in Vitro Metabolism of Anticancer N-(2-Hydroxyethyl)-3,5-dinitrobenzamide 2-Mustard Prodrugs Drug Metab. Dispos., February 1, 2008; 36(2): 353 - 360. [Abstract] [Full Text] [PDF]